Novartis AG (NVS) : Analyst Rating Update

Novartis AG (NVS) : The consensus on Novartis AG (NVS) based on 10 analyst recommendation on the company stock is 2.53, which is interpreted as a Hold recommendation. Zacks Investment Research has issued a rank of 3 which endorses a Hold on the stock. However, 4 brokers have a differing view as they consider the stock to be a Strong Buy at current levels. 4 experts consider that the stocks earnings and the quoted price is in harmony, hence, they give it a Hold rating. 2 analyst sees the stock overvalued at current levels and advises a Strong Sell on the stock.

Novartis AG (NVS) : The highest level Novartis AG (NVS) is projected to reach is $115 for the short term and the lowest estimate is at $81. The consolidated price target from 4 rating analysts who initiate coverage on the stock is $92.75 and the possibility the share price can swing is $15.2.

Novartis AG (NYSE:NVS): During Wednesdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $81.13 and $80.85 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $82.08. The buying momentum continued till the end and the stock did not give up its gains. It closed at $82.02, notching a gain of 0.37% for the day. The total traded volume was 1,345,465 . The stock had closed at $81.72 on the previous day.

Also, Morgan Stanley downgrades its rating on Novartis AG (NYSE:NVS). Analysts at the Morgan Stanley have a current rating of Underperform on the shares. The shares were previously rated Equal-weight. The rating by the firm was issued on April 12, 2016. The company shares have dropped -17.48% from its 1 Year high price. On Jul 20, 2015, the shares registered one year high at $106.84 and the one year low was seen on Apr 1, 2016. The 50-Day Moving Average price is $79.09 and the 200 Day Moving Average price is recorded at $77.19.

Novartis AG is a holding company that, through its subsidiaries, is engaged in development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals around the world. Its portfolio includes medicines, eye care, generic pharmaceuticals, preventive vaccines and over-the-counter (OTC) products. The Companys segments include Pharmaceuticals, which include patent-protected prescription medicines; Alcon, which include surgical, ophthalmic pharmaceutical and vision care products; Sandoz, which include generic pharmaceuticals, and Consumer Health, which includes the OTC Division. Pharmaceuticals products include Afinitor/Votubia, Exjade, Galvus, Exforge and Voltaren, among others. Its Sandoz products include Valsartan (Diovan), Cyclophosphamide injection and AirFluSal Forspiro, among others. Its OTC offers readily available consumer medicine. The Company operates Admune Therapeutics as a wholly owned subsidiary.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.